623 related articles for article (PubMed ID: 30565239)
1. What did we learn from CTLA-4 insufficiency on the human immune system?
Mitsuiki N; Schwab C; Grimbacher B
Immunol Rev; 2019 Jan; 287(1):33-49. PubMed ID: 30565239
[TBL] [Abstract][Full Text] [Related]
2. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.
Schubert D; Bode C; Kenefeck R; Hou TZ; Wing JB; Kennedy A; Bulashevska A; Petersen BS; Schäffer AA; Grüning BA; Unger S; Frede N; Baumann U; Witte T; Schmidt RE; Dueckers G; Niehues T; Seneviratne S; Kanariou M; Speckmann C; Ehl S; Rensing-Ehl A; Warnatz K; Rakhmanov M; Thimme R; Hasselblatt P; Emmerich F; Cathomen T; Backofen R; Fisch P; Seidl M; May A; Schmitt-Graeff A; Ikemizu S; Salzer U; Franke A; Sakaguchi S; Walker LSK; Sansom DM; Grimbacher B
Nat Med; 2014 Dec; 20(12):1410-1416. PubMed ID: 25329329
[TBL] [Abstract][Full Text] [Related]
3. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects.
Schwab C; Gabrysch A; Olbrich P; Patiño V; Warnatz K; Wolff D; Hoshino A; Kobayashi M; Imai K; Takagi M; Dybedal I; Haddock JA; Sansom DM; Lucena JM; Seidl M; Schmitt-Graeff A; Reiser V; Emmerich F; Frede N; Bulashevska A; Salzer U; Schubert D; Hayakawa S; Okada S; Kanariou M; Kucuk ZY; Chapdelaine H; Petruzelkova L; Sumnik Z; Sediva A; Slatter M; Arkwright PD; Cant A; Lorenz HM; Giese T; Lougaris V; Plebani A; Price C; Sullivan KE; Moutschen M; Litzman J; Freiberger T; van de Veerdonk FL; Recher M; Albert MH; Hauck F; Seneviratne S; Pachlopnik Schmid J; Kolios A; Unglik G; Klemann C; Speckmann C; Ehl S; Leichtner A; Blumberg R; Franke A; Snapper S; Zeissig S; Cunningham-Rundles C; Giulino-Roth L; Elemento O; Dückers G; Niehues T; Fronkova E; Kanderová V; Platt CD; Chou J; Chatila TA; Geha R; McDermott E; Bunn S; Kurzai M; Schulz A; Alsina L; Casals F; Deyà-Martinez A; Hambleton S; Kanegane H; Taskén K; Neth O; Grimbacher B
J Allergy Clin Immunol; 2018 Dec; 142(6):1932-1946. PubMed ID: 29729943
[TBL] [Abstract][Full Text] [Related]
4. Lessons from CTLA-4 deficiency and checkpoint inhibition.
Lo B; Abdel-Motal UM
Curr Opin Immunol; 2017 Dec; 49():14-19. PubMed ID: 28806575
[TBL] [Abstract][Full Text] [Related]
5. Immune dysregulation syndrome with de novo CTLA4 germline mutation responsive to abatacept therapy.
Ureshino H; Koarada S; Kamachi K; Yoshimura M; Yokoo M; Kubota Y; Ando T; Ichinohe T; Morio T; Kimura S
Int J Hematol; 2020 Jun; 111(6):897-902. PubMed ID: 31993940
[TBL] [Abstract][Full Text] [Related]
6. Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation.
Wing K; Yamaguchi T; Sakaguchi S
Trends Immunol; 2011 Sep; 32(9):428-33. PubMed ID: 21723783
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
Kumar P; Bhattacharya P; Prabhakar BS
J Autoimmun; 2018 Dec; 95():77-99. PubMed ID: 30174217
[TBL] [Abstract][Full Text] [Related]
8. EFIS Lecture: Understanding the CTLA-4 checkpoint in the maintenance of immune homeostasis.
Walker LSK
Immunol Lett; 2017 Apr; 184():43-50. PubMed ID: 28216262
[TBL] [Abstract][Full Text] [Related]
9. CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade.
Garcia-Perez JE; Baxter RM; Kong DS; Tobin R; McCarter M; Routes JM; Verbsky J; Jordan MB; Dutmer CM; Hsieh EWY
Front Immunol; 2019; 10():998. PubMed ID: 31156616
[TBL] [Abstract][Full Text] [Related]
10. Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types.
Oyewole-Said D; Konduri V; Vazquez-Perez J; Weldon SA; Levitt JM; Decker WK
Front Immunol; 2020; 11():608024. PubMed ID: 33384695
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes.
Gámez-Díaz L; Grimbacher B
Biomed J; 2021 Aug; 44(4):400-411. PubMed ID: 34384744
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic options for CTLA-4 insufficiency.
Egg D; Rump IC; Mitsuiki N; Rojas-Restrepo J; Maccari ME; Schwab C; Gabrysch A; Warnatz K; Goldacker S; Patiño V; Wolff D; Okada S; Hayakawa S; Shikama Y; Kanda K; Imai K; Sotomatsu M; Kuwashima M; Kamiya T; Morio T; Matsumoto K; Mori T; Yoshimoto Y; Dybedal I; Kanariou M; Kucuk ZY; Chapdelaine H; Petruzelkova L; Lorenz HM; Sullivan KE; Heimall J; Moutschen M; Litzman J; Recher M; Albert MH; Hauck F; Seneviratne S; Pachlopnik Schmid J; Kolios A; Unglik G; Klemann C; Snapper S; Giulino-Roth L; Svaton M; Platt CD; Hambleton S; Neth O; Gosse G; Reinsch S; Holzinger D; Kim YJ; Bakhtiar S; Atschekzei F; Schmidt R; Sogkas G; Chandrakasan S; Rae W; Derfalvi B; Marquart HV; Ozen A; Kiykim A; Karakoc-Aydiner E; Králíčková P; de Bree G; Kiritsi D; Seidel MG; Kobbe R; Dantzer J; Alsina L; Armangue T; Lougaris V; Agyeman P; Nyström S; Buchbinder D; Arkwright PD; Grimbacher B
J Allergy Clin Immunol; 2022 Feb; 149(2):736-746. PubMed ID: 34111452
[TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
Kumar P; Saini S; Prabhakar BS
Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
[TBL] [Abstract][Full Text] [Related]
14. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.
Kuehn HS; Ouyang W; Lo B; Deenick EK; Niemela JE; Avery DT; Schickel JN; Tran DQ; Stoddard J; Zhang Y; Frucht DM; Dumitriu B; Scheinberg P; Folio LR; Frein CA; Price S; Koh C; Heller T; Seroogy CM; Huttenlocher A; Rao VK; Su HC; Kleiner D; Notarangelo LD; Rampertaap Y; Olivier KN; McElwee J; Hughes J; Pittaluga S; Oliveira JB; Meffre E; Fleisher TA; Holland SM; Lenardo MJ; Tangye SG; Uzel G
Science; 2014 Sep; 345(6204):1623-1627. PubMed ID: 25213377
[TBL] [Abstract][Full Text] [Related]
15. In Vitro Analysis of CTLA-4-Mediated Transendocytosis by Regulatory T Cells.
Waters E; Williams C; Kennedy A; Sansom DM
Methods Mol Biol; 2023; 2559():171-187. PubMed ID: 36180633
[TBL] [Abstract][Full Text] [Related]
16. Treg and CTLA-4: two intertwining pathways to immune tolerance.
Walker LS
J Autoimmun; 2013 Sep; 45(100):49-57. PubMed ID: 23849743
[TBL] [Abstract][Full Text] [Related]
17. Different Apples, Same Tree: Visualizing Current Biological and Clinical Insights into CTLA-4 Insufficiency and LRBA and DEF6 Deficiencies.
Gámez-Díaz L; Seidel MG
Front Pediatr; 2021; 9():662645. PubMed ID: 33996698
[TBL] [Abstract][Full Text] [Related]
18. Neurological manifestation of immune system dysregulation resulting from CTLA-4 receptor mutation: a case report.
Kolcava J; Litzman J; Bednarik J; Stulik J; Stourac P
Mult Scler Relat Disord; 2020 Oct; 45():102313. PubMed ID: 32623363
[TBL] [Abstract][Full Text] [Related]
19. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
20. Murine LRBA deficiency causes CTLA-4 deficiency in Tregs without progression to immune dysregulation.
Burnett DL; Parish IA; Masle-Farquhar E; Brink R; Goodnow CC
Immunol Cell Biol; 2017 Oct; 95(9):775-788. PubMed ID: 28611475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
